Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22651558 | 0.90 | MMP13 (0.38) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL19245050 | 0.86 | MMP13 (0.36) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL21447817 | 0.84 | AAK1 (0.35) | MMP13AAK1 | |
| SCHEMBL9447853 | 0.83 | MMP13 (0.38) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL20586574 | 0.83 | MMP13 (0.38) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL66573 | 0.83 | HDAC1 (0.41) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL20826464 | 0.83 | HDAC1 (0.41) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL18248156 | 0.83 | MMP13 (0.38) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL67491 | 0.83 | HDAC1 (0.41) | MMP13MEN1GAAKMT2AAAK1 | |
| SCHEMBL8906653 | 0.82 | FOLH1 (0.38) | MMP13MEN1GAAKMT2AAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018048-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2022-03-31 | — | — | US | disclosed |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2020-11-12 | — | — | US | disclosed |
| US-10344056-B2 | Anthelmintic depsipeptide compounds | Boehringer Ingelheim Animal Health USA Inc. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | MERIAL INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10344056-B2 | Anthelmintic depsipeptide compounds | VIP, PREP, DNPEP | MMP13 440/4885MEN1 1735/4885GAA 2706/4885 |
| US-12018048-B2 | Anthelmintic depsipeptide compounds | VIP, DNPEP, DPEP1 | MMP13 434/4885MEN1 1915/4885GAA 1692/4885 |
| US-20170233438-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MMP13 440/4885MEN1 1735/4885GAA 2706/4885 |
| US-20220098241-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MMP13 440/4885MEN1 1735/4885GAA 2706/4885 |
| US-20200354408-A1 | ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS | VIP, PREP, DNPEP | MMP13 504/4885MEN1 1902/4885GAA 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.